Value
6.3/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 10.0 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 8.3 |
| Analyst target | 6.0 |
- ▸Forward P/E: 14.0x
OFIX · Why this verdict
Why Orthofix Medical (OFIX) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.1/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Implied volatility of 159% reflects the market pricing in significant event risk ahead of the 2026-08-04 earnings report. Risk breakdown | Implied volatility should moderate below 100% once the earnings catalyst passes without a major surprise. | →Stable |
| CounterElevated implied volatility heading into an earnings date for a small-cap medical device company is a normal, structural feature of the options market rather than a distinct warning signal. | ||
Orthofix Medical is in a confirmed downtrend, with its 200-day moving average sloping -4.8% per 30 days, and triggered a death-cross hard block in the engine's momentum gate. Engine gate (failed) | The stock should reclaim its 200-day moving average within 2 quarters for the downtrend to be considered broken. | →Stable |
| CounterThe engine separately reads this as an early recovery attempt, since MACD is improving through the death cross and RSI at 60 suggests renewed buying interest rather than continued decline. | ||
Orthofix trades at an attractive 14.0x forward P/E and has beaten earnings estimates in 3 of the last 4 quarters, averaging a 76.6% surprise, with 28% analyst upside to target. Bull case | The forward P/E should stay below 16x and the beat streak should continue at the 2026-08-04 report. | →Stable |
| CounterA cheap valuation combined with a confirmed technical downtrend and weak growth can be a classic value trap where the multiple stays low because the market correctly expects further deterioration. | ||
The company fails the Rule of 40 test at just 4, versus the 40 benchmark, reflecting weak combined growth and profitability even though free cash flow is positive despite a GAAP loss. Quality breakdown | The Rule of 40 score should improve toward breakeven, closer to 20-30, within 12 months if either growth accelerates or margins improve. | →Stable |
| CounterThe FCF-positive-despite-GAAP-loss profile is itself a meaningful quality signal, at a 3% FCF margin and 5.5% FCF yield, that a low Rule of 40 score alone doesn't capture. | ||
Insiders sold a net $377,394 over the trailing 90 days, registering as minor severity at 0.094% of market cap per the engine's insider assessment. Insider | Insider selling severity should stay at minor or below over the next two quarters for this not to be read as an escalating warning sign. | →Stable |
| CounterThe insider data also shows 9 separate buy transactions worth $2.29 million against only 3 sells worth $2.67 million over the same 90-day window, indicating two-sided, not one-directional, insider activity. | ||
Implied volatility of 159% reflects the market pricing in significant event risk ahead of the 2026-08-04 earnings report.
→StableRisk breakdown
- Expectation
- Implied volatility should moderate below 100% once the earnings catalyst passes without a major surprise.
CounterElevated implied volatility heading into an earnings date for a small-cap medical device company is a normal, structural feature of the options market rather than a distinct warning signal.
Orthofix Medical is in a confirmed downtrend, with its 200-day moving average sloping -4.8% per 30 days, and triggered a death-cross hard block in the engine's momentum gate.
→StableEngine gate (failed)
- Expectation
- The stock should reclaim its 200-day moving average within 2 quarters for the downtrend to be considered broken.
CounterThe engine separately reads this as an early recovery attempt, since MACD is improving through the death cross and RSI at 60 suggests renewed buying interest rather than continued decline.
Orthofix trades at an attractive 14.0x forward P/E and has beaten earnings estimates in 3 of the last 4 quarters, averaging a 76.6% surprise, with 28% analyst upside to target.
→StableBull case
- Expectation
- The forward P/E should stay below 16x and the beat streak should continue at the 2026-08-04 report.
CounterA cheap valuation combined with a confirmed technical downtrend and weak growth can be a classic value trap where the multiple stays low because the market correctly expects further deterioration.
The company fails the Rule of 40 test at just 4, versus the 40 benchmark, reflecting weak combined growth and profitability even though free cash flow is positive despite a GAAP loss.
→StableQuality breakdown
- Expectation
- The Rule of 40 score should improve toward breakeven, closer to 20-30, within 12 months if either growth accelerates or margins improve.
CounterThe FCF-positive-despite-GAAP-loss profile is itself a meaningful quality signal, at a 3% FCF margin and 5.5% FCF yield, that a low Rule of 40 score alone doesn't capture.
Insiders sold a net $377,394 over the trailing 90 days, registering as minor severity at 0.094% of market cap per the engine's insider assessment.
→StableInsider
- Expectation
- Insider selling severity should stay at minor or below over the next two quarters for this not to be read as an escalating warning sign.
CounterThe insider data also shows 9 separate buy transactions worth $2.29 million against only 3 sells worth $2.67 million over the same 90-day window, indicating two-sided, not one-directional, insider activity.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Orthofix Medical trades at an attractive valuation with a strong earnings beat streak, but a confirmed technical downtrend and weak growth via a Rule of 40 failure keep the setup speculative despite offsetting free cash flow generation.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.6 |
| FCF quality | 4.5 |
| Moat | 5.4 |
| Rule of 40 | 3.0 |
| Piotroski F | 8.9 |
- ▸FCF-positive despite GAAP loss (FCF margin 3%, FCF yield 5.5%)
- ▸No competitive moat
- ▸Rule of 40: 4 (fail)
- ▸Strong Piotroski F-Score: 8/9
Growth
2.9/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 2.9 |
Momentum
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.9 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 8.9 |
- ▸Overbought bear rally (RSI 72)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -4.9%/30d — confirmed downtrend
Sentiment
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 6.3 |
| Price target | 8.5 |
- ▸LLM news sentiment: +0.30 (n=9)
- ▸Light analyst coverage (4.0) — signal dampened
- ▸Analyst upside: 30%
Insider
5.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 6.5 |
| holder change | 5.0 |
- ▸Modest insider selling — $377,394 (0.094% of mkt cap)
Peer rank
3.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 9.5 |
| quality rank | 3.7 |
| growth rank | 1.6 |
Technical
1.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 1.0 |
| 52w position | 3.6 |
| gap | 3.0 |
- ▸Extreme gap up (6.8%) - may pull back
Risk (lower is worse)
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.2 |
| days to cover | 6.8 |
| volatility | 0.0 |
| put call | 6.7 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 8.7 |
| debt equity | 7.4 |
- ▸High IV: 168%
- ▸Above max pain $5
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING).
Engine technical detail
verdict_path:
L4:PATH_F_SELL|L3:NEWS_MOD=+2Passed (5)
- MOMENTUM:7.6>=5.5
- INSIDER:OK
- EARNINGS_PROXIMITY:29d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.7<1.5@spot
Warning (2)
- DEATH_CROSS:momentum=7.6>=5.0 recovering
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.67
Upside
+10.1%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 72
EdgeCatalyst-Driven — Earnings in 29d with 3/4 beat streak
SuitabilityAggressive — MCap $0.4B<$5B
Investment implication
The F-path SELL output reflects an overall score of 5.1 below the 5.4 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Momentum at 7.6) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:0.7<1.5@spot) reinforce the read. Current asymmetry R:R is 0.67 — supplementary context, not the trigger for this path.
The strongest dimensions are Momentum at 7.6, Sentiment at 7.0, and Catalyst at 6.9; the weakest are Technical at 1.9, Growth at 2.9, and Peer rank at 3.7. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 0.67 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Confirmed Downtrend Death Cross
Trip ifThe 200-day moving average slope stays below 0% or the stock fails to reclaim the 200-day MA within 2 quarters.
- P2Attractive Valuation Earnings Beat
Trip ifEPS surprise falls below 0% at the 2026-08-04 report, breaking the beat pattern.
- P3Weak Growth Rule Of 40 Failure
Trip ifRevenue growth stays below 2% YoY while FCF margin falls below 0% for 2 consecutive quarters.
- P4Modest Insider Selling
Trip ifInsider selling severity escalates beyond minor, with net selling exceeding 0.5% of market cap, within the next 90 days.
- P5Elevated Implied Volatility Earnings Risk
Trip ifImplied volatility stays above 140% for 2 consecutive months after the earnings report passes.